Amy Comstock Rick has over 30 years of experience leading organizations, executing strategy, transforming organizational culture, building consensus, and advocating policies across constituencies.
In her role as principal at Leavitt Partners, an HMA Company, she leads the Medicines Development Modernization Initiative and advises on federal health care policy, the U.S. Food and Drug Administration (FDA), National Institutes of Health (NIH), drug development and research educational convenings, and patient engagement initiatives.
Prior to joining Leavitt Partners, Amy served as president and chief executive officer (CEO) of the Food and Drug Law Institute (FDLI), a multi-stakeholder, educational non-profit organization dedicated to providing topical and timely materials to inform public policy, law, and regulation regarding food and drug law. She was also previously CEO of the Parkinson’s Action Network (PAN), a Washington D.C.-based national nonprofit focused on educating the public and government leaders on better policies for research and therapy development and an improved quality of life for people living with Parkinson’s disease.
Amy served as president of the Coalition for the Advancement of Medical Research, on the NIH Institute for Neurological Disorders and Stroke’s Advisory Council, and on the boards of directors of the National Health Council and the American Brain Coalition. Before joining PAN, she was the Senate-confirmed director of the U.S. Office of Government Ethics and the associate counsel to the President in the White House Counsel’s Office.
Amy received a Bachelor of Arts degree in American history from Bard College and a Juris Doctor degree from the University of Michigan. She also serves on the board of directors of Research!America.